Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Share-based Compensation (2016 - 2026)

Heron Therapeutics filings provide 15 years of Share-based Compensation readings, the most recent being $3.0 million for Q1 2026.

  • On a quarterly basis, Share-based Compensation rose 18.52% to $3.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $10.8 million, a 10.7% decrease, with the full-year FY2025 number at $10.3 million, down 20.24% from a year prior.
  • Share-based Compensation hit $3.0 million in Q1 2026 for Heron Therapeutics, up from $2.2 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $13.9 million in Q2 2023 to a low of $2.2 million in Q4 2025.
  • Median Share-based Compensation over the past 5 years was $4.3 million (2023), compared with a mean of $6.0 million.
  • Biggest five-year swings in Share-based Compensation: surged 34.26% in 2023 and later crashed 67.12% in 2024.
  • Heron Therapeutics' Share-based Compensation stood at $10.5 million in 2022, then tumbled by 58.87% to $4.3 million in 2023, then plummeted by 46.92% to $2.3 million in 2024, then dropped by 5.05% to $2.2 million in 2025, then soared by 36.58% to $3.0 million in 2026.
  • The last three reported values for Share-based Compensation were $3.0 million (Q1 2026), $2.2 million (Q4 2025), and $2.9 million (Q3 2025) per Business Quant data.